Showing 141-160 of 503 for: Cochrane Systematic Reviews > Neurologic 
- Dietary interventions for multiple sclerosis
Cochrane Systematic Reviews, 5-Nov-2012
Clinical and experimental data suggest that certain dietary regimens, particularly those including polyunsaturated fatty acids (PUFAs) and vitamins, might improve outcomes in people with multiple sclerosis (MS). Diets and dietary supplements are much used
- Dipyrone for acute primary headaches
Cochrane Systematic Reviews, 11-Jul-2014
Dipyrone is used to treat headaches in many countries, but is not available in others (particularly the USA and UK) because of its association with potentially life-threatening blood dyscrasias such as agranulocytosis.
- Donepezil for dementia due to Alzheimer's disease
Cochrane Systematic Reviews, 3-Nov-2008
Alzheimer's disease is the most common cause of dementia in older people. One of the aims of therapy is to inhibit the breakdown of a chemical neurotransmitter, acetylcholine, by blocking the relevant enzyme. This can be done by a group of chemicals known
- Donepezil for mild cognitive impairment
Cochrane Systematic Reviews, 9-Nov-2010
Problems with memory which do not meet the diagnostic criteria for dementia, usually called mild cognitive impairment (MCI), can be the first sign of an impending dementia, particularly Alzheimer's disease (AD). There is no consensus on a definition or di
- Donepezil for vascular cognitive impairment
Cochrane Systematic Reviews, 3-Nov-2008
Vascular disease is the second commonest cause of dementia after Alzheimer's disease. There are difficulties in classifying patients with this type of cognitive impairment owing to varied clinical presentation and different types of arterial disease. Ther
- Dopamine agonist therapy in early Parkinson's disease
Cochrane Systematic Reviews, 12-Nov-2008
Dopamine agonists are being used increasingly as first line treatment for Parkinson's disease, but there remains uncertainty about their clinical and cost-effectiveness relative to levodopa.
- Dopamine agonists for the treatment of restless legs syndrome
Cochrane Systematic Reviews, 24-Mar-2011
According to clinical guidelines, dopamine agonists are the first-line treatment of restless legs syndrome (RLS).
- Drug management for acute tonic-clonic convulsions including convulsive status epilepticus in children
Cochrane Systematic Reviews, 7-Sep-2010
Tonic-clonic (grand mal) convulsions and convulsive status epilepticus (currently defined as a grand mal convulsion lasting at least 30 minutes) are medical emergencies and demand urgent and appropriate anticonvulsant treatment. Benzodiazepines (midazolam
- Drug therapy for chronic idiopathic axonal polyneuropathy
Cochrane Systematic Reviews, 3-Apr-2013
Chronic idiopathic axonal polyneuropathy is an insidiously progressive sensory or sensorimotor polyneuropathy that affects elderly people. Although severe disability or handicap does not occur, it reduces quality of life. This is an updated review.
- Drug therapy for delirium in terminally ill adult patients
Cochrane Systematic Reviews, 4-Oct-2012
Delirium is a syndrome characterised by a disturbance of consciousness (often fluctuating), cognition and perception. In terminally ill patients it is one of the most common causes of admission to clinical care. Delirium may arise from any number of cause
- Drug therapy for obstructive sleep apnoea in adults
Cochrane Systematic Reviews, 30-Apr-2013
The treatment of choice for moderate to severe obstructive sleep apnoea (OSA) is continuous positive airways pressure (CPAP) applied via a mask during sleep. However, this is not tolerated by all individuals and its role in mild OSA is not proven. Drug th
- Drug therapy for the management of cancer-related fatigue
Cochrane Systematic Reviews, 1-Aug-2010
This review is an update of a previously published review in The Cochrane Database of Systematic Reviews (Issue 1 2008). Cancer-related fatigue (CRF) is common, under-recognised and difficult to treat. There have been studies looking at drug interventions
- Drug treatment for facioscapulohumeral muscular dystrophy
Cochrane Systematic Reviews, 11-Aug-2008
Facioscapulohumeral muscular dystrophy is a progressive muscle disease which has no agreed treatment. Early suggestions that corticosteroids might be helpful were not supported by a subsequent open label study. The beta 2 adrenergic agonist albuterol, als
- Drug treatment for myotonia
Cochrane Systematic Reviews, 10-May-2011
Abnormal delayed relaxation of skeletal muscles, known as myotonia, can cause disability in myotonic disorders. Sodium channel blockers, tricyclic antidepressive drugs, benzodiazepines, calcium-antagonists, taurine and prednisone may be of use in reducing
- Drug treatment for spinal muscular atrophy type I
Cochrane Systematic Reviews, 13-Mar-2012
Spinal muscular atrophy (SMA) is caused by degeneration of anterior horn cells of the spinal cord, which leads to progressive muscle weakness. Children with SMA type I will never be able to sit without support and usually die by the age of two years. Ther
- Drug treatment for spinal muscular atrophy types II and III
Cochrane Systematic Reviews, 13-Mar-2012
Spinal muscular atrophy (SMA) is caused by degeneration of anterior horn cells, which leads to progressive muscle weakness. Children with SMA type II do not develop the ability to walk without support and have a shortened life expectancy, whereas children
- Drugs for preventing migraine headaches in children
Cochrane Systematic Reviews, 11-Jul-2014
It has been estimated that about 10 per cent of children between 6 and 20 years of age suffer from migraine, and that children with migraine lose one and a half weeks more schooling per year than their peers. Prophylactic drugs can be prescribed when chil
- Early (< 7 days) systemic postnatal corticosteroids for prevention of bronchopulmonary dysplasia in preterm infants
Cochrane Systematic Reviews, 21-Oct-2021
Bronchopulmonary dysplasia (BPD) remains a major problem for infants born extremely preterm. Persistent inflammation in the lungs is important in its pathogenesis. Systemic corticosteroids have been used to prevent or treat BPD because of their potent ant
- Early versus late antiepileptic drug withdrawal for people with epilepsy in remission
Cochrane Systematic Reviews, 29-Apr-2015
Epilepsy is a chronic neurological disorder which affects millions of people around the world. Antiepileptic drugs (AED) are the main interventions used to prevent seizures and control epilepsy. Although effective in most cases, AEDs are related to long-t
- Early volume expansion for prevention of morbidity and mortality in very preterm infants
Cochrane Systematic Reviews, 12-May-2009
Reduced perfusion of organs such as the brain, heart, kidneys and the gastrointestinal tract may lead to acute dysfunction and be associated with permanent injury. Various strategies have been used to provide cardiovascular support to preterm infants incl
